About transcode therapeutics inc - RNAZ
TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company was founded by Robert Michael Dudley, Zdravka Medarova, and Anna Moore in January 2016 and is headquartered in Boston, MA.
RNAZ At a Glance
TransCode Therapeutics, Inc.
6 Liberty Square
Boston, Massachusetts 02109
| Phone | 1-857-837-3099 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -16,754,971.00 | |
| Sector | Health Technology | Employees | 7 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
RNAZ Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.302 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | -0.008 |
RNAZ Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -2,393,567.286 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
RNAZ Liquidity
| Current Ratio | 2.559 |
| Quick Ratio | 2.559 |
| Cash Ratio | 2.096 |
RNAZ Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -268.85 |
| Return on Equity | N/A |
| Return on Total Capital | 846.021 |
| Return on Invested Capital | N/A |
RNAZ Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | -1.933 |
| Total Debt to Total Assets | 0.525 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |